Pacira Pharmaceuticals (PCRX) Reaches $44.00 After 6.00% Up Move; 3 Analysts Bullish TransGlobe Energy (TSE:TGL)

June 19, 2017 - By Louis Casey

Among 6 analysts covering TransGlobe Energy Corp. (TSE:TGL), 3 have Buy rating, 1 Sell and 2 Hold. Therefore 50% are positive. TransGlobe Energy Corp. had 22 analyst reports since August 14, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, February 3 by TD Securities. The firm has “Sector Underperformer” rating given on Thursday, January 14 by IBC. TD Securities maintained the stock with “Buy” rating in Friday, March 10 report. The firm has “Buy” rating given on Thursday, December 22 by TD Securities. The stock of TransGlobe Energy Corporation (TSE:TGL) has “Buy” rating given on Friday, January 27 by TD Securities. The company was maintained on Tuesday, November 8 by Scotia Capital. TD Securities maintained TransGlobe Energy Corporation (TSE:TGL) rating on Friday, August 14. TD Securities has “Buy” rating and $6 target. The rating was maintained by Scotia Capital on Wednesday, April 12 with “Sector Perform”. Paradigm Research upgraded TransGlobe Energy Corporation (TSE:TGL) on Monday, October 5 to “Buy” rating. See TransGlobe Energy Corporation (TSE:TGL) latest ratings:

12/04/2017 Broker: Scotia Capital Rating: Sector Perform New Target: $3.00 Maintain
10/03/2017 Broker: TD Securities Rating: Buy New Target: $3.25 Maintain
03/02/2017 Broker: TD Securities Rating: Buy New Target: $3.25 Maintain
27/01/2017 Broker: TD Securities Rating: Buy New Target: $3.25 Maintain
26/01/2017 Broker: Scotia Capital Rating: Sector Perform Old Target: $3.50 New Target: $3.25 Target Down
22/12/2016 Broker: TD Securities Rating: Buy New Target: $3.50 Maintain

The stock of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) is a huge mover today! About 179,684 shares traded. Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has risen 12.40% since June 19, 2016 and is uptrending. It has underperformed by 4.30% the S&P500.The move comes after 5 months positive chart setup for the $1.71B company. It was reported on Jun, 19 by Barchart.com. We have $46.64 PT which if reached, will make NASDAQ:PCRX worth $102.60M more.

Pacira Pharmaceuticals, Inc. is a holding company. The company has market cap of $1.71 billion. The Firm is a pharmaceutical firm focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. It currently has negative earnings. The Company’s lead product candidate is EXPAREL , which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia.

Among 15 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX), 10 have Buy rating, 1 Sell and 4 Hold. Therefore 67% are positive. Pacira Pharmaceuticals has $113 highest and $31 lowest target. $62.82’s average target is 42.77% above currents $44 stock price. Pacira Pharmaceuticals had 30 analyst reports since July 28, 2015 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, January 3. On Friday, July 1 the stock rating was downgraded by Brean Capital to “Hold”. The stock of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has “Mkt Outperform” rating given on Tuesday, January 5 by JMP Securities. The firm has “Buy” rating by Canaccord Genuity given on Monday, May 29. Nomura initiated the shares of PCRX in report on Tuesday, September 29 with “Buy” rating. On Friday, February 26 the stock rating was maintained by Brean Capital with “Buy”. Wedbush maintained Pacira Pharmaceuticals Inc (NASDAQ:PCRX) rating on Wednesday, October 19. Wedbush has “Outperform” rating and $93 target. As per Friday, October 7, the company rating was reinitiated by Brean Capital. Bank of America upgraded the stock to “Neutral” rating in Monday, August 3 report. The firm has “Buy” rating given on Thursday, November 3 by Mizuho.

Since January 17, 2017, it had 0 buys, and 11 selling transactions for $3.94 million activity. $576,122 worth of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) shares were sold by STACK DAVID M. Shares for $1.02 million were sold by Scibetta James S on Monday, May 15. On Monday, June 5 Jones James B sold $33,227 worth of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) or 767 shares. $49,650 worth of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) was sold by Riker Lauren Bullaro on Wednesday, June 7. $1.07 million worth of stock was sold by Williams Kristen Marie on Monday, May 15. Another trade for 768 shares valued at $33,271 was sold by Braunstein Scott.

Investors sentiment increased to 1.18 in 2016 Q4. Its up 0.08, from 1.1 in 2016Q3. It improved, as 21 investors sold Pacira Pharmaceuticals Inc shares while 53 reduced holdings. 34 funds opened positions while 53 raised stakes. 38.95 million shares or 1.71% more from 38.30 million shares in 2016Q3 were reported. 1.08 million were reported by State Street. Hodges Cap Mgmt holds 159,000 shares or 0.24% of its portfolio. Dekabank Deutsche Girozentrale invested in 0.01% or 20,015 shares. Ameriprise Financial holds 31,817 shares or 0% of its portfolio. The New York-based Bancorp Of Ny Mellon has invested 0% in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). Goldman Sachs Grp holds 0% or 107,837 shares. 2,201 were reported by Kbc Gru Nv. 31,077 are owned by Walleye Trading Limited Liability Corp. Morgan Stanley accumulated 0% or 120,568 shares. Century Companies has 53,494 shares. Hanson Mcclain invested in 335 shares. Putnam Invs Ltd Llc holds 0% or 34,549 shares in its portfolio. Synovus Financial invested 0% of its portfolio in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). Armistice Capital Ltd Co stated it has 400,000 shares. Weiss Multi has 8,000 shares for 0.01% of their portfolio.